FindTrial
Sign In

Clostridium difficile vaccine

BIOLOGICAL6 trials

Sponsors

Sanofi, Pfizer

Conditions

Clostridium Difficile Associated DiseaseClostridium Difficile InfectionClostridium Infections

Phase 1

Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers
CompletedNCT00127803
SanofiClostridium Infections
Start: 2005-07-31End: 2006-03-31Updated: 2012-09-14
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
CompletedNCT02725437
PfizerClostridium Difficile Associated Disease
Start: 2016-02-29End: 2017-02-28Updated: 2018-07-13

Phase 2

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
CompletedNCT02117570
PfizerClostridium Difficile Associated Disease
Start: 2014-07-31End: 2015-12-31Updated: 2017-01-30
A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
CompletedNCT02561195
PfizerClostridium Difficile Associated Disease
Start: 2015-07-16End: 2020-02-13Updated: 2021-03-08

Phase 3

Clostridium Difficile Vaccine Efficacy Trial
CompletedNCT03090191
PfizerClostridium Difficile Infection
Start: 2017-03-29End: 2021-12-21Updated: 2023-02-13
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
CompletedNCT03579459
PfizerClostridium Difficile Associated Disease
Start: 2018-07-31End: 2019-08-06Updated: 2023-01-19

Related Papers

CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of <i>Clostridioides difficile</i> Infection
Clinical Infectious Diseases2024-08-2417 citations
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age
Vaccine2023-11-1712 citations
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a <i>Clostridioides difficile</i> Vaccine in Healthy US Adults Aged 65 to 85 Years
The Journal of Infectious Diseases2023-08-0113 citations
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults.
2019-04-055 citations
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years
Clinical Infectious Diseases2019-03-1851 citations